Skye Bioscience Treats First Patient In Part C Expansion Study Of CBeyond Phase 2a Trial To Characterize Safety And PK At Exposures To Challenge Peripheral Restriction Of Nimacimab Through IV Administration Over 16 Weeks Of Treatment

Skye Bioscience, Inc. (NASDAQ: SKYE) has initiated the treatment of its first patient in the Part C expansion study of the CBeyond Phase 2a trial, focusing on the safety and pharmacokinetics of nimacimab administered intravenously over 16 weeks. The study includes two cohorts receiving 400 mg and 600 mg doses of nimacimab, compared to a placebo, with a total of 16 doses administered weekly. Enrollment in the higher dose cohort is dependent on a favorable safety review after four weeks of treatment in the initial cohort. Topline data from this expansion study is expected to be reported in the fourth quarter of 2026.